Differential modulation of mediator release from human basophils and mast cells by mizolastine

Clinical and Experimental Allergy

Volumn 34, Issue 2, 2004, Pages 241-249

  Triggiani, M ^a   Giannattasio, G ^a   Balestrieri, B ^a   Granata, F ^a   Gelb, M H ^b   De Paulis, A ^a   Marone, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Basophils; Cysteinyl leukotriene C4; Histamine; IL 4; Mast cells; Mizolastine

Indexed keywords

ARACHIDONIC ACID; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; ICOSANOID; IMMUNOGLOBULIN E; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MIZOLASTINE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN D2; PYRROLIDINE DERIVATIVE;

ARTICLE; BASOPHIL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG ALVEOLUS CELL; MAST CELL; MEDIATOR RELEASE; MOBILIZATION; PRIORITY JOURNAL;

ANTIBODIES, ANTI-IDIOTYPIC; BASOPHILS; BENZIMIDAZOLES; CELL MEMBRANE; CELLS, CULTURED; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN E; LUNG; MAST CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRROLIDINES; STIMULATION, CHEMICAL;

EID: 1542375246     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.01851.x     Document Type: Article

References (51)

1. Marone G, Casolaro V, Patella V et al. Molecular and cellular biology of mast cells and basophils. Int Arch Allergy Immunol 1997; 114:207-17.
2. Drazen JM, Austen KF, Lewis RA et al. Comparative airway and vascular activities of leukotrienes C and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77:4354-8.
3. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
4. Schroeder JT, MacGlashan DW Jr, Kagey-Sobotka A et al. IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J Immunol 1994; 153:1808-17.
5. Hill SJ, Ganellin CR, Timmerman H et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49:253-78.
6. 1- antihistamines. Clin Allergy Immunol 2002; 17:141-78.
7. Staub A, Bovet D. Actions de la thymoethyl-diethylamine (929F) et des éthers phénoliques sur le choc anaphylactique du cobaye. CR Soc Biol 1937; 128:818-25.
8. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999; 29:1593-6.
9. 1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32:489-98.
10. Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980; 69:663-7.
11. Nabe M, Agrawal DK, Sarmiento EU, Townley RG. Inhibitory effect of terfenadine on mediator release from human blood basophils and eosinophils. Clin Exp Allergy 1989; 19:515-20.
12. + cells. Clin Exp Allergy 1997; 27:559-67.
13. Gibbs BF, Vollrath IB, Albrecht C et al. Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:573-8.
14. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31:1369-77.
15. Fadel R, David B, Herpin-Richard N et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating factor (PAF-acether) in man. J Allergy Clin Immunol 1990; 86:314-20.
16. Ciprandi G, Buscaglia S, Pesce G et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early-and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95:612-21.
17. Redier H, Chanez P, De Vos C et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90:215-24.
18. Brostoff J, Fitzharris P, Dunmore C et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996; 51:320-5.
19. Leynadier F, Bousquet J, Murrieta M, Attali P. Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol 1996; 76:163-8.
20. Slater JW, Zechnich AD, Haxby DG. Second-generation anti-histamines: a comparative review. Drugs 1999; 57:31-47.
21. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneim-Forsch Drug Res 1998; 48:173-8.
22. Oddera S, Cagnoni F, Dellacasa P, Canonica GW. Effects of mizolastine in vitro on human immunocompetent and airway cells: evidence for safety and additional property. Int Arch Allergy Immunol 2000; 123:162-9.
23. 1 receptor antagonist mizolastine in the rodent. Arzneim-Forsch Drug Res 1995; 45:559-68.
24. Vargaftig BB. Mechanisms of experimental bronchopulmonary hyperresponsiveness as related to eosinophils. In: Langer SZ, Church MK, Vargaftig BB, Nicosia S, eds. New developments in the therapy of allergic disorders and asthma. Basel: Karger, 1993; 27-32.
25. Carayol N, Crampette L, Mainprice B et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002; 57:1067-70.
26. Sudo K, Nagai K, Yamada N. Inhibitory effect of mizolastine on 5-lypoxygenase. Jpn Pharmacol Ther 1998; 26:155-7.
27. Triggiani M, Casolaro V, Genovese A et al. Heterogeneity of human FcεRI-bearing cells. Ann Allergy 1993; 71:133-8.
28. Marone G, Spadaro G, De Marino V et al. Immunopharmacology of human mast cells and basophils. Int J Clin Lab Res 1998; 28:12-22.
29. Warner JA, Peters SP, Lichtenstein LM et al. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J Leukoc Biol 1989; 45:558-71.
30. 2 α blocks arachidonic acid release in a variety of mammalian cells. Biochim Biophys Acta 2001; 1513:160-6.
31. + cells and inhibit IL-13 synthesis through interaction with formyl peptide receptors. J Immunol 2002; 169:4559-67.
32. Triggiani M, Hubbard WC, Chilton FH. Synthesis of 1-acyl-2-acetyl-sn- glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol 1990; 144:4773-80.
33. Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 1974; 57:383-94.
34. Patella V, Marinó I, Lamparter B et al. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J Immunol 1995; 154:2855-65.
35. 4 generation, but not histamine release or IL-4 production from human basophils. J Immunol 1999; 162:4198-206.
36. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993; 177:605-11.
37. Stenson WF, Parker CW, Sullivan TJ. Augmentation of IgE-mediated release of histamine by 5-hydroxyeicosatetraenoic acid and 12-hydroxyeicosatetraenoic acid. Biochem Biophys Res Commun 1980; 96:1045-52.
38. Peters SP, Siegel MI, Kagey-Sobotka A, Lichtenstein LM. Lipoxygenase products modulate histamine release in human basophils. Nature 1981; 292:455-7.
39. Peters SP, Kagey-Sobotka A, MacGlashan DW Jr et al. The modulation of human basophil histamine release by products of the 5-lipoxygenase pathway. J Immunol 1982; 129:797-803.
40. 4 release in human basophils. J Allergy Clin Immunol 1998; 102:512-20.
41. 1-receptor- antagonist drugs. N Engl J Med 1994; 330:1663-70.
42. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996; 98:S307-18.
43. 1-receptor effects of antihistamines. Clin Exp Allergy 1999; 29 Suppl. 3):39-48.
44. Redrup AC, Howard BP, MacGlashan DW Jr et al. Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J Immunol 1998; 160:1957-64.
45. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokinet 2001; 40:501-7.
46. 2 receptors. J Immunol 1998; 161:2586-93.
47. 3 receptors: stimulation of IL-10 production. J Immunol 2000; 164:2964-70.
48. Mazzoni A, Young HA, Spitzer JH et al. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108:1865-73.
49. Marone G, Kagey-Sobotka A, Lichtenstein LM. Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol 1979; 123:1669-77.
50. 2O. J Immunol 1982; 128:2067-72.
51. 2. J Med Chem 2000; 43:1041-4.